Scarica l'app Stockscreener
0.9238
7.28%
-0.0725
Dopo l'orario di chiusura:
.94
0.0162
+1.75%
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
SBI Securities Co. Ltd. Invests $28,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - The Bakersfield Californian
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough - Simply Wall St
5 Best Stem Cell Companies to Invest In (March 2025) - Securities.io
Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89% - Yahoo Finance
Head-To-Head Comparison: Sangamo Therapeutics (NASDAQ:SGMO) versus Novavax (NASDAQ:NVAX) - Defense World
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Isaralgagene civaparvovec (ST-920) for Fabry disease – Fabry... - Fabry Disease News
Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha
Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com Nigeria
Sangamo reports positive Fabry disease gene therapy results - MSN
Sangamo reports updated data for gene therapy candidate ST-920 - MSN
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace
Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St
Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
HC Wainwright Has Bearish Forecast for SGMO FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Thalassemia Market Research by Treatment Type, Type, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - The Eastern Progress Online
Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright - Defense World
Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Truist Financial Has Lowered Expectations for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $5.17 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 - MarketBeat
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - Citeline News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Q3 2018 First Look: Dancing With Data (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
0.55%
1.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):